Contractor directory
UEI FKP3JZ9RUNY9 · CAGE 7A5L2

Cidara Therapeutics Inc

Cidara Therapeutics Inc received $0 in federal prime contract obligations in the 12 months ending Oct 5, 2026, down 100.0% from $58.1M the year before, and $58.1M since FY2022. Its largest customer is the Department of Health and Human Services.

See 1 contracts ending in the next 18 months ↓
Obligations, latest 12 months
$0
down 100.0% vs. $58.1M
Since FY2022
$58.1M
1 awards
Awards with activity
1
Latest 12 months
Most recent action
Jun 2, 2026
First seen Sep 30, 2025

Contractor details

Unique Entity ID (UEI)
FKP3JZ9RUNY9
CAGE code
7A5L2
Headquarters
SAN Diego, CA
Business size
Small Business

As recorded on this UEI's most recent prime contract action in USAspending.gov. Confirm current registration and certifications in SAM.gov.

Obligations by fiscal year

Net prime contract obligations by federal fiscal year.

FY2025
$58.1M
FY2026
$0

Top agencies

Funding agencies ranked by obligations since FY2022.

Funding agencyLatest 12 moSince FY2022
Department of Health and Human Services$0$58.1M

Top NAICS codes

Industry codes agencies recorded on this contractor's awards, since FY2022.

NAICSIndustryLatest 12 moSince FY2022
541714Research and Development in Biotechnology (except Nanobiotechnology)$0$58.1M

What it sells

Product and service codes (PSC) on this contractor's awards, since FY2022.

PSCDescriptionSince FY2022
AN14Health R&D services; Health Care services; R&D Administrative Expenses$58.1M

Contracts ending in the next 18 months

This contractor's largest awards whose current period of performance ends soon. Options and extensions often move these dates.

AwardAgencyObligatedCurrent end
75A50125C00017
Department of Health and Human Services
DEVELOPMENT OF CD388 AS A LONG-LASTING PROPHYLACTIC ANTI-VIRAL OPTION FOR PROTECTION AGAINST THE HEALTH IMPACTS CAUSED BY INFLUENZA
$58.1MSep 29, 2027

Recent awards

This contractor's newest prime contract awards, most recent first.

AwardAgencyObligatedAwarded
75A50125C00017
Department of Health and Human Services
DEVELOPMENT OF CD388 AS A LONG-LASTING PROPHYLACTIC ANTI-VIRAL OPTION FOR PROTECTION AGAINST THE HEALTH IMPACTS CAUSED BY INFLUENZA
$58.1MSep 30, 2025

Prime contracts (award types A–D) from USAspending.gov through Oct 5, 2026. Subcontracts are not included. Net obligations include deobligations and corrections.

Ready to win more?

Ready to connect your pursuit work?

GovEagle gives BD directors, capture managers, and proposal teams one AI workspace from pipeline through proposal, with CMMC/FedRAMP Certified compliance built in.